NovoCure Limited

XNASHealth care

Last traded price · USD

$14.87

+10.72%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 04:47 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $13.43
Volume: 1.6M
Day's high: —
Day's low: —

In brief

NovoCure Limited is a health care company listed on Nasdaq, valued at about $1.74B.
Its shares closed at $14.61 on 4 Nov 2026, up 21.8% over the past year.
From India you can buy NVCR in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy NovoCure Limited (NVCR) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole NVCR share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade NVCR options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Below its 50- and 200-day averages
The 4 Nov 2026 close of $14.61 was 6.3% below its 50-day average ($15.58) and 1.4% below its 200-day average ($14.82). It has closed below the 200-day for 9 sessions, since 23 Oct 2026. The 50-day average crossed above the 200-day on 7 May 2026, 125 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Volume 3.9× its 30-session average on 29 Oct 2026
29 Oct 2026 volume of 6.0M shares was 3.9× the average of the 30 sessions before it (1.5M), as the price fell 7.5%. SPY traded 1.0× its own average that session.
Daily volume against a 30-session baseline · as of 29 Oct 2026
Ahead of SPY, behind its sector fund XLV over 1 year
1 month: −2.4% (SPY −1.6%, XLV +13.5%). 3 months: −9.0% (SPY −0.4%, XLV +15.5%). 1 year: +21.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: NVCR, SPY and XLV · as of 4 Nov 2026
7.7 days to cover short interest
12.8M shares were sold short at the 15 Oct 2026 settlement, 11.0% of the 116.9M shares outstanding; covering them would take 7.7 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
41% of the way up its 52-week range
Closed at $14.61 on 4 Nov 2026: 31.9% below the 52-week high of $21.45 (24 Jul 2026) and 48.8% above the low of $9.82 (9 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−2.4%

6 months−11.4%

1 year+21.8%

5 years−86.3%

Newswire

About

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Website

Notable moves

December 2, 2024
+48.95%
June 6, 2023
−43.04%
January 5, 2023
+68.45%

NovoCure Limited

XNASHealth care

Last traded price · USD

$14.87

+10.72%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 04:47 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $13.43
Volume: 1.6M
Day's high: —
Day's low: —

In brief

NovoCure Limited is a health care company listed on Nasdaq, valued at about $1.74B.
Its shares closed at $14.61 on 4 Nov 2026, up 21.8% over the past year.
From India you can buy NVCR in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy NovoCure Limited (NVCR) shares from India?

Do I need the price of a whole NVCR share to invest?

How much can I invest in US stocks in a year?

Can I trade NVCR options or futures?

Insights

Quotes run fifteen minutes behind.

Below its 50- and 200-day averages
The 4 Nov 2026 close of $14.61 was 6.3% below its 50-day average ($15.58) and 1.4% below its 200-day average ($14.82). It has closed below the 200-day for 9 sessions, since 23 Oct 2026. The 50-day average crossed above the 200-day on 7 May 2026, 125 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Volume 3.9× its 30-session average on 29 Oct 2026
29 Oct 2026 volume of 6.0M shares was 3.9× the average of the 30 sessions before it (1.5M), as the price fell 7.5%. SPY traded 1.0× its own average that session.
Daily volume against a 30-session baseline · as of 29 Oct 2026
Ahead of SPY, behind its sector fund XLV over 1 year
1 month: −2.4% (SPY −1.6%, XLV +13.5%). 3 months: −9.0% (SPY −0.4%, XLV +15.5%). 1 year: +21.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: NVCR, SPY and XLV · as of 4 Nov 2026
7.7 days to cover short interest
12.8M shares were sold short at the 15 Oct 2026 settlement, 11.0% of the 116.9M shares outstanding; covering them would take 7.7 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
41% of the way up its 52-week range
Closed at $14.61 on 4 Nov 2026: 31.9% below the 52-week high of $21.45 (24 Jul 2026) and 48.8% above the low of $9.82 (9 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−2.4%

6 months−11.4%

1 year+21.8%

5 years−86.3%

Newswire

About

Website

Notable moves

December 2, 2024
+48.95%
June 6, 2023
−43.04%
January 5, 2023
+68.45%

NovoCure Limited

NovoCure Limited in brief

Below its 50- and 200-day averages

Volume 3.9× its 30-session average on 29 Oct 2026

Ahead of SPY, behind its sector fund XLV over 1 year

7.7 days to cover short interest

41% of the way up its 52-week range

NovoCure Limited

NovoCure Limited in brief

Below its 50- and 200-day averages

Volume 3.9× its 30-session average on 29 Oct 2026

Ahead of SPY, behind its sector fund XLV over 1 year

7.7 days to cover short interest

41% of the way up its 52-week range